５．Department of Bacteriology Ⅱ

mediates promoter inversions of phase-variable mpl
lipoprotein genes in Mycoplasma penetrans. Microbiology,155: 1241-1249, 2009.

1）Kato H, Kato H, Nakamura M, Iwashima Y, Nakamura A,and Ueda R.: Rapid analysis of Clostridium difficile strains

9）Kataoka M, Yamamoto A, Ochiai M, Harashima A, Nagata

recovered from hospitalized patients by using the slpA

N, Hasegawa H, Kurata T, and Horiuchi Y.: Comparison ofsequence typing. J Infect Chemother, 15: 199-202, 2009.

acellular pertussis based combination vaccines by Japanese2）Kuroda M, Katano H, Nakajima N, Tobiume M, Ainai A,control tests for toxicities and laboratory models for local

Sekizuka T, Hasegawa H, Tashiro M, Sasaki Y, Arakawa Y,
Hata S, Watanabe M, and Sata T.: Characterization ofquasispecies ofpandemic(A/H1N1/2009)

byM.: Virulence genes, quinolone and fluoroquinolone

using

a

resistance, and phylogenetic background of uropathogenic

next-generation DNA sequencer. PloS One 5; e10256, doi:

Escherichia coli strains isolated in Japan. Jpn J Infect Dis,10.1371/journal.pone. 0010256, 2010.

63 (2): 113-5, 2009.

NovoInfluenza

10）Kawamura-Sato K, Yoshida R, Shibayama K, and Ohta

A virusDe

2009

reaction. Vaccine, 27: 1881-1888, 2009.

sequencing

3）Kimura K, Wachino, J, Kurokawa H, Suzuki S, Yamane K,11）Mori S, Shibayama K, Wachino J, and Arakawa Y.:

Shibata S, and Arakawa Y.: Practical disk diffusion test for

Crystallization and preliminary X-ray analysis of thedetecting group B streptococcus with reduced penicillin

diadenosine

susceptibility. J Clin Microbiol, 47: 4154-4157, 2009.

from Mycobacterium tuberculosis H37Rv. Acta Crystallogr,4 ） Nagano N, Kimura K, Nagano Y, Yakumaru H, andArakawa Y.: Molecular characterization of group B
streptococci

withreducedpenicillin

5',5'''-P1,P4-tetraphosphate

phosphorylase

F66: 279-281, 2010.
12）Mori S, Shibayama K, Wachino J, and Arakawa Y.:

susceptibilityPurification and molecular characterization of a novel

recurrently isolated from a sacral decubitus ulcer. J

diadenosine 5',5'''-P(1),P(4)-tetraphosphate phosphorylase

Antimicrobial Chemother, 64: 1326-1328, 2009.

from Mycobacterium tuberculosis H37Rv. Protein Expr5）Honma Y, Yoshii Y, Watanabe Y, Aoki N, Komiya T, IwakiPurif, 69: 99-105, 2010.

M, Arai H, Arakawa Y, Takahashi M, and Kimura H.: A13）Kamachi K, Fukuda T, Han HJ, Toyoizumi-Ajisaka H,

Case of Afebrile Pneumonia Caused by Non-Toxigenic

Mochida K, Konda T, Horiuchi Y, Arakawa Y, and DPT

Corynebacterium diphtheriae. Jpn J Infect Dis, 62 (4):technical committee of the association of biological327-329, 2009.

manufactures of Japan.: Genetic verification of Bordetella6）Katsukawa C, Kawahara R, Inoue K, Ishii A, Yamagishi H,pertussis seed strains used for production of Japanese

Kida K, Nishino S, Nagahama S, Komiya T, Iwaki M, andacellular pertussis vaccines. Biologicals, 38: 290-293,Takahashi

2010.

M.:

Toxigenic

Corynebacterium

ulcerans

Isolated from the Domestic Dog for the First Time in Japan.

14）Kamano H, Mori T, Maeta H, Taminato T, Ishida T,

Jpn J Infect Dis, 62 (2): 171-172, 2009.

Kishimoto N, Katami T, Sato M, Kamachi K, and Mochida7）Hall AJ, Cassiday PK, Bernard KA, Bolt F, Steigerwalt AG,

Y.: Analysis of Bordetella pertussis agglutinin titers during

Bixler D, Pawloski LC, Whitney AM, Iwaki M, Baldwin A,

an outbreak of pertussis at a university in Japan. Jpn J

Dowson CG, Komiya T, Takahashi M, Hinrikson AP, andInfect Dis, 63: 108-112, 2010.

8)

Tondella ML.: A Novel Corynebacterium diphtheriae15）Sakamoto T, Torii Y, Takahashi M, Ishida S, Goto Y,

Isolated from Domestic Cats (Felis catus). Emerg InfectNakano H, Harakawa T, Ginnaga A, Kozaki S, and Kaji R.:

Dis, 16 (4): 688-691, 2010.

Quantitative determination of the biological activity ofHorino A, Kenri T, Sasaki Y, Okamura N, and Sasaki T.:

botulinum toxin type A by measuring the compound muscle

Identification of a site-specific tyrosine recombinase that1

action potential (CMAP) in rats. Toxicon, 54: 857-861,2009.
16）Torii Y, Goto Y, Takahashi M, Ishida S, Harakawa T,
Sakamoto T, Kaji R, Kozaki S, and Ginnaga A.:
Quantitative determination of biological activity of
botulinum toxins utilizing compound muscle action
potentials (CMAP), and comparison of neuromusculartransmission blockage and muscle flaccidity among toxins.
Toxicon, 55: 407-414, 2010.
17）Torii Y, Takahashi M, Ishida S, Goto Y, Nakahira S,Harakawa T, Kaji R, Kozaki S, and Ginnaga A.:
Quantification of potency of neutralizing antibodies tobotulinum toxin using compound muscle action potential(CMAP). Toxicon, 55: 662-665, 2010.

2